Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Wages, Salaries and Other

Cytosorbents (CTSO) Long-Term Debt Issuances (2017 - 2019)

Cytosorbents filings provide 6 years of Long-Term Debt Issuances readings, the most recent being $5.0 million for Q3 2019.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $5.0 million in Q3 2019 year-over-year; TTM through Dec 2020 was $5.0 million, a 0.0% change, with the full-year FY2025 number at $2.5 million, down 83.48% from a year prior.
Long-Term Debt Issuances hit $5.0 million in Q3 2019 for Cytosorbents, up from $666667.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $5.0 million in Q2 2017 to a low of $666667.0 in Q1 2018.
Median Long-Term Debt Issuances over the past 3 years was $5.0 million (2017), compared with a mean of $3.6 million.